Passage Bio, Inc. (PASG) Stock Score, Valuation & Financial Research

Passage Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PASG

Passage Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.76. These figures are a research snapshot, not a buy or sell recommendation.

What Passage Bio, Inc. does

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Passage Bio is a clinical-stage genetic medicines company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and strategic financing to fund the research, development, and clinical trials of its gene therapy product candidates.

Products and services

  • The company develops genetic medicines for neurodegenerative diseases, primarily utilizing AAV-based gene therapy vectors to deliver therapeutic genes to patients.

Customer types

Patients with neurodegenerative diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturing organizations for the production of clinical trial materials and drug product candidates. Source

Business relationships and partnerships

  • University of Pennsylvania (Penn) — A strategic research collaboration and license agreement providing the company with access to gene therapy technology and intellectual property. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company competes with various entities developing gene therapies and treatments for neurodegenerative disorders, including those with greater financial and technical resources. Source

Business strengths to evaluate

  • Proprietary AAV-based gene therapy platform Source

Business risks and research considerations

  • History of operating losses and potential inability to achieve profitability Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PASG financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.76
Market capitalization:
12.08M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -36.11M
Free cash flow:
USD -31.51M
Cash:
USD 24.16M
Total debt:
USD 24.01M
EPS:
USD -11.33

What stands out

  • Free cash flow is USD -31.51M, negative for the stored period.
  • The balance sheet shows USD 24.16M of cash versus USD 24.01M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 145K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PASG

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PASG fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does PASG's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for PASG to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of PASG's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PASG

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.